Showing 421-430 of 5956 results for "".
Autoimmune Rheumatic Disease
https://modernod.com/mod-issues/2026-mar-apr/autoimmune-rheumatic-disease/56859/Learn these clues to see whether you may be dealing with more than dry eye disease.First Robotic Cataract Surgery Performed
https://modernod.com/podcasts/eyewire-news-the-podcast/first-robotic-cataract-surgery-performed/39875/Uday Devgan, MD, shares his experience performing the world’s first robotic cataract surgery; Konan Medical receives CE Mark for its objectiveFIELD Analyzer perimetry device; and Biotech Healthcare launches a new full visual range EDOF IOL. Learn more about your ad choices. Visit megaphone.fm/adchoKeep Your IOL Knowledge Sharp
https://modernod.com/podcasts/the-mod-pod/keep-your-iol-knowledge-sharp/36888/On this month's episode of The MOD Pod Cecelia Koetting, OD, FAAO, Dipl ABO, welcomes guests Eugene Shifrin, OD, FAAO, and Thomas Chester, OD. Dr. Shifrin shares tips and best practices for enhancing patient outcomes with light adjustable lenses, which he details in a recent article in Modern OptomeFirst Commerical Surgeries Performed with MacTel Therapy
https://modernod.com/podcasts/eyewire-news-the-podcast/first-commerical-surgeries-performed-with-mactel-therapy/37097/Charles Wykoff, MD, PhD, shares his experience performing the first commercial case for a patient with MacTel; VSY Biotechnology launches its Enova Hydrophobic IOLs with a new preloaded delivery system; and an app is launched that syncs AI directly to leading OCT devices. Learn more about your ad chTryptyr Now Available in US
https://modernod.com/podcasts/eyewire-news-the-podcast/tryptyr-now-available-in-us/37095/Alcon launches its recently approved dry eye drug Tryptyr; a potential $1 billion deal is made to advance extended-release therapies for eye diseases; and two companies with late-stage AMD drug candidates complete phase 3 enrollment. Learn more about your ad choices. Visit megaphone.fm/adchoicesHarrow Adds Biosimilars to US Portfolio
https://modernod.com/podcasts/eyewire-news-the-podcast/harrow-adds-biosimilars-to-us-portfolio/37094/Harrow enters a deal to expand it biosimilar pharma portfolio; the first gene-agnostic therapy to restore vision in RP patients advances; and Aldeyra provides an update on its dry eye drug candidate reproxalap. Learn more about your ad choices. Visit megaphone.fm/adchoicesEMPOWER - Cornea Health Diagnostic Tools
https://modernod.com/podcasts/the-mod-pod/empower-cornea-health-diagnostic-tools/39861/In the fourth podcast episode, Jacob Lang, OD, FAAO, leads a discussion on functional vision testing, workflow integration, and real-world cases with Paul Hammond, OD, and Jason Compton, OD, FAAO, that demonstrates how advanced diagnostics improve outcomes and strengthen patient trust. The panel alsEMPOWER - Corneal Health and the Relevance of Specialty Lenses
https://modernod.com/topics/corneaanterior-segment/corneal-health-and-the-relevance-of-specialty-lenses/36879/Staying ahead in patient care and business growth requires the right knowledge and tools. In the first installment of the EMPOWER: Business + Optometric Specialty Care series, Jacob Lang, OD, FAAO, Dipl ABO; Diana Chu, OD; and Ashley Tucker, OD, FAAO, FSLS, Dipl ABO, explore the critical role of corB+L Receives Approval in Europe for LuxLife IOL
https://modernod.com/podcasts/eyewire-news-the-podcast/bl-receives-approval-in-europe-for-luxlife-iol/37084/Bausch + Lomb receives CE Mark for a new full range of vision IOL; Aldeyra plans to once again resubmit a new drug application to the FDA for dry eye drug candidate reproxalap; and Topcon makes several deals to advance its AI and digital health solutions Learn more about your ad choices. Visit meg90. Focus Shift: From IOLs to LALs ft. Dr. Marcella Labelle
https://modernod.com/podcasts/four-eyes/90-focus-shift-from-iols-to-lals-ft-dr-marcella-labelle/37040/In this episode of Four Eyes, we sit down with Dr. Marcella LaBelle, an optometrist in Alberta with over 20 years of experience in refractive surgical care, to dive into the world of intraocular and light-adjustable lenses. From identifying ideal candidates (even those without cataracts) to demystif